Product Information
RINVOQ ER 30 MG TABLET is a brand product labeled by AbbVie Inc., priced at $229.2939 per EA under NDC 00074231030. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Aug 16, 2019.
Strength
30 mg/1
Manufacturer
AbbVie Inc.NDC
00074231030
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
UPADACITINIBApproval Type
New Drug (NDA)
FDA Application
NDA211675FDA Approved
8/16/2019
On Market Since
8/16/2019
Pharmacological Classes
Price Statistics
The NADAC for RINVOQ ER 30 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 10.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $229.2939 per EA |
|---|---|
| All-time high | $229.2939 (Sep 30, 2026) |
| All-time low | $206.7811 (Jul 17, 2024) |
| 52-week high | $229.2939 |
| 52-week low | $217.9290 |
| Median price | $217.9693 |
| Average price | $217.9793 |
| Largest weekly change | +5.0% (Jan 14, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Upadacitinib market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Upadacitinib market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Janus Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RINVOQ ER 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RINVOQ ER 30 MG TABLET, manufactured by AbbVie Inc., is $229.2939 per EA (NDC 00074231030), effective Sep 30, 2026.
How has the price of RINVOQ ER 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for RINVOQ ER 30 MG TABLET has risen 10.9%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for RINVOQ ER 30 MG TABLET?
Since Apr 17, 2024, the NADAC for RINVOQ ER 30 MG TABLET has ranged from a low of $206.7811 (Jul 17, 2024) to a high of $229.2939 (Sep 30, 2026), with a median of $217.9693 per EA.
Are there cheaper alternatives to RINVOQ ER 30 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of RINVOQ ER 30 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RINVOQ ER 30 MG TABLET?
RINVOQ ER 30 MG TABLET (NDC 00074231030) is labeled by AbbVie Inc., and CMS classifies it as a brand product.